Clinical Trial of Synkavit for Bronchus Carcinoma
Author Information
Author(s): T. J. Deeley
Primary Institution: Hammersmith Hospital
Hypothesis
Does Synkavit improve survival rates in patients with carcinoma of the bronchus when combined with X-ray therapy?
Conclusion
The study found a small improvement in survival rates for patients receiving Synkavit alongside X-ray therapy.
Supporting Evidence
- Patients receiving X-ray therapy alone survived for an average of 4-8 months.
- Patients receiving X-ray therapy and Synkavit survived for an average of 7-5 months.
- Patients receiving intravenous Synkavit had a mean survival time of 11 months.
Takeaway
This study tested a medicine called Synkavit to see if it helps people with lung cancer live longer when used with X-ray treatment.
Methodology
Patients were randomly assigned to receive either X-ray therapy alone or X-ray therapy with intravenous Synkavit.
Limitations
The treatment groups were not strictly comparable as some received radical and some palliative X-ray therapy.
Participant Demographics
All patients had histologically proved anaplastic carcinoma of the bronchus and no evidence of spread outside the chest.
Want to read the original?
Access the complete publication on the publisher's website